Recent headlines from the sources AlphaScala monitors. AlphaScala analysis is published in the main market section.
Seeking Alpha analyst keeps 2026 S&P 500 target. The analyst shifts from financials to tech and industrials. AI infrastructure spending is the driver.
Powerlaw Corp. trades at an 8% discount to NAV after its top SPCX holding declined. The next NAV report may show whether the gap persists.
S&P 500 and Nasdaq rose Friday, posting weekly gains on tech strength. Apple and Microsoft each climbed more than 1%. The 10-year yield fell 3 bps to 4.28% after a soft consumer sentiment print. The Fed meets next week.
CRDO investment case rests on full-year AI data-center pipeline, not quarterly results. AlphaScale score 61/100. Stock page carries full data.
Talen Energy scores a Weak 32 on AlphaScala's model, signaling elevated risk despite ongoing buybacks. The utility's post-restructuring repurchase program has yet to improve fundamentals.
Banzai International launched a $1M baby shelf stock offering Thursday. The marketing tech company's shares fell 6% after hours. Aegis Capital is sole book-runner.
FMTM returned 63% since March. Its holdings trade at 28x earnings, a 40% premium to the S&P 500. The July retail sales report is the next test for a fund that needs earnings delivery to justify its valuation.
SK Hynix begins trading in the U.S. at $120 per ADR, giving American investors direct exposure to the memory-chip maker that supplies Nvidia's next-gen AI chips.
SK hynix started trading on Nasdaq under ticker SKHY, giving U.S. investors a direct exchange listing for the memory chip maker. The ADR IPO opens a new channel for institutional and retail exposure.
FELC: Impressive Bounceback From The War; Upgrading To Hold
SK Hynix ADRs opened at $149 on the Nasdaq, giving U.S. investors direct access to the dominant HBM supplier whose entire 2024 production is sold out.
AstraZeneca shares fell sharply, outstripping the estimated hit from the Wainua program. Analysts said the move suggests broader concerns beyond the rare liver drug.
The FOMC meets June 10-11 for rate decision and dot plot. Apple, the S&P 500's largest stock, trades at 28x earnings. Options imply a 1.2% move on decision day.
TeraWulf's infrastructure and power contracts give it a cost edge over CoreWeave, Nebius, and IREN, per a Seeking Alpha analysis. Alpha Score data shows weak ratings for CRWV, NBIS, and IREN.
Nifty 50 opened above 24,100, shifting the intraday structure. The 24,260 resistance is the next test. A break opens 24,350. The dip-buying zone sits at 24,170-24,210.
WD-40 posted record Q3 sales but faces margin pressure. FY2026 sales guidance set at $675M-$690M, homecare brands reclassified, $100M buyback authorized.
AMAT has fallen 20% in weeks as AI capex concerns mount. Alpha Score 68 signals moderate risk. The next catalyst is the quarterly report in late August. What would confirm or reverse the setup?
Grand Canyon Education's strong growth hasn't created a valuation edge. The stock prices in the upbeat outlook, leaving regulatory and competitive shifts as risks.
Micron dropped nearly 30% after a Q4 revenue guide came in $380M below consensus. The gap reflects an HBM capacity wall, not a demand shock. A Q4 beat in September is the next test.
A trader spent $24 million on a QQQ call spread that needs the Nasdaq 100 to hit an all-time high by July 31. The breakeven is near $750, less than $2 above the June high. Here is what the trade says about market conviction.
Camtek's next quarterly report will test whether its 30x earnings premium holds. The AI packaging boom is visible, but concentration risk is real.
Preferred Bank's July 22 Q2 call, with CEO Li Yu and management, will test loan growth, net interest margin, and credit quality for California-focused commercial lenders.
Jefferies sees FY2028 EPS of $30-$40 as Broadcom locks in Google TPU revenue through 2031 and adds an OpenAI custom chip deal, with $500B potential upside.
Calumet's business has improved, yet the stock's 60% rally leaves little upside. A Seeking Alpha analyst sees fair value near $18-$20, implying 10% downside.
Meta's Muse Spark 1.1 takes aim at OpenAI and Anthropic with stronger agentics, multistep reasoning, and a price advantage that could shift enterprise AI spending.
Tarsus Pharma's iRenix acquisition adds a device for Demodex blepharitis to complement Xdemvy. The slide deck outlines the strategy but leaves financial terms and launch timing for the next earnings call.
Nifty 50 sank 2.1% to 23,882 after Trump's Iran remarks. Analysts expect volatility to persist as global risk-off deepens. The sell-off was broad-based across sectors.
A merger arb skeptic made an exception for Caesars Entertainment. The analyst cited a rare asymmetric setup. The deal's regulatory and financing path now matters.
SpaceX slid below its $150 debut price for a second day after the Nasdaq 100 inclusion. Analyst ratings are mostly bullish; MoffettNathanson is neutral and CFRA recommends selling.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser. If you have an ad-blocker enabled you may be blocked from ...